Kinases in cerebral cavernous malformations: Pathogenesis and therapeutic targets

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Cerebral cavernous malformations (CCMs) are genetic vascular lesions in the central nervous system causing stroke-like symptoms and seizures.
• Identification of CCM1, CCM2, and CCM3 genes has elucidated molecular mechanisms underlying CCM pathogenesis.

Purpose of the Study:

• To review the general aspects of CCM disease.
• To discuss kinase-mediated signaling pathways involved in CCM pathogenesis.
• To explore current potential therapeutic strategies for CCM.

Main Methods:

• Literature review of CCM disease mechanisms and signaling pathways.
• Analysis of kinase signaling cascades (e.g., MEKK3/MEK5/ERK5, Rho/Rock, CCM3/GCKIII, PI3K/mTOR).
• Examination of preclinical and clinical trial data for CCM therapeutics.

Main Results:

• Kinases play a central role in CCM pathogenesis, with several key signaling cascades identified.
• Inhibitors targeting Rho/Rock signaling and other kinase components have shown potential in preclinical and clinical studies.
• Drug development targeting kinase signaling pathways is advancing.

Conclusions:

• Kinase-targeted drug development presents a viable non-surgical treatment option for CCM disease.
• Further research into kinase inhibitors may address the unmet need for effective CCM therapies.
• Understanding kinase signaling is crucial for developing novel therapeutic interventions for CCM.